PHARMADIX: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
PHARMADIX
Largest movements
- Receivables within one year +€78,636
up €78,636 (+338.7%), from €23,215 to €101,851
- Cash -€33,983
down €33,983 (-34.2%), from €99,380 to €65,397
mainly Receivables within one year (-€78,636) and Tax, wage and social debts (-€21,198)
- Stocks and contracts -€7,125
down €7,125 (-12.9%), from €55,430 to €48,305
- Reserves +€62,389
up €62,389 (+47.5%), from €131,337 to €193,726
- Tax, wage and social debts -€21,198
down €21,198 (-80.3%), from €26,400 to €5,202
- Gross operating margin +€21,767
up €21,767 (+35.7%), from €60,907 to €82,674
- Other operating charges -€1,818
no longer reported in 2025 (was €1,818)
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €186,918 | €225,469 | +€38,551 | +20.6% |
| Fixed assets | 21/28 | €8,892 | €8,398 | -€494 | -5.6% |
| Tangible fixed assets | 22/27 | €8,892 | €8,398 | -€494 | -5.6% |
| Plant, machinery and equipment | 23 | €8,892 | €8,398 | -€494 | -5.6% |
| Current assets | 29/58 | €178,026 | €217,071 | +€39,045 | +21.9% |
| Stocks and contracts in progress | 3 | €55,430 | €48,305 | -€7,125 | -12.9% |
| Stocks | 30/36 | €55,430 | €48,305 | -€7,125 | -12.9% |
| Amounts receivable within one year | 40/41 | €23,215 | €101,851 | +€78,636 | +338.7% |
| Other amounts receivable | 41 | €23,215 | €101,851 | +€78,636 | +338.7% |
| Cash at bank and in hand | 54/58 | €99,380 | €65,397 | -€33,983 | -34.2% |
| Deferred charges and accrued income | 490/1 | - | €1,518 | +€1,518 | |
| Total equity and liabilities | 10/49 | €186,918 | €225,469 | +€38,551 | +20.6% |
| Equity | 10/15 | €141,337 | €203,726 | +€62,389 | +44.1% |
| Contributions | 10/11 | €10,000 | €10,000 | = | 0.0% |
| Reserves | 13 | €131,337 | €193,726 | +€62,389 | +47.5% |
| Distributable reserves | 133 | €131,337 | €193,726 | +€62,389 | +47.5% |
| Amounts payable | 17/49 | €45,581 | €21,743 | -€23,837 | -52.3% |
| Amounts payable within one year | 42/48 | €45,581 | €21,002 | -€24,579 | -53.9% |
| Current portion of amounts payable after more than one year | 42 | €1,714 | - | -€1,714 | |
| Trade debts | 44 | €17,467 | €15,800 | -€1,667 | -9.5% |
| Suppliers | 440/4 | €17,467 | €15,800 | -€1,667 | -9.5% |
| Taxes, remuneration and social security | 45 | €26,400 | €5,202 | -€21,198 | -80.3% |
| Taxes | 450/3 | €26,400 | €5,202 | -€21,198 | -80.3% |
| Accrued charges and deferred income | 492/3 | - | €741 | +€741 | |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €494 | €494 | = | 0.0% |
| Other operating charges | 640/8 | €1,818 | - | -€1,818 | |
| Gross operating margin | 9900 | €60,907 | €82,674 | +€21,767 | +35.7% |
| Operating profit (loss) | 9901 | €58,594 | €82,180 | +€23,586 | +40.3% |
| Financial income | 75/76B | €176 | €84 | -€91 | -52.0% |
| Recurring financial income | 75 | €176 | €84 | -€91 | -52.0% |
| Financial charges | 65/66B | €251 | €480 | +€229 | +91.3% |
| Recurring financial charges | 65 | €251 | €480 | +€229 | +91.3% |
| Profit (loss) for the period before taxes | 9903 | €58,519 | €81,784 | +€23,265 | +39.8% |
| Income taxes | 67/77 | €20,202 | €19,395 | -€807 | -4.0% |
| Profit (loss) for the period | 9904 | €38,317 | €62,389 | +€24,072 | +62.8% |
| Profit (loss) for the period to be appropriated | 9905 | €38,317 | €62,389 | +€24,072 | +62.8% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 5 October 2026 via checked.be.